Literature DB >> 20624773

A new apolipoprotein E mutation, apoE Las Vegas, in a European-American with lipoprotein glomerulopathy.

Andrew S Bomback1, Huijuan Song, Vivette D D'Agati, Scott D Cohen, Alison Neal, Gerald B Appel, Brad H Rovin.   

Abstract

Lipoprotein glomerulopathy is a rare disease diagnosed by unique histopathologic findings of glomerular capillary dilatation by lipoprotein thrombi. The disease is caused by mutations in apoE, the gene that encodes apolipoprotein E. To date, <80 cases have been reported in the medical literature, nearly all of which are from Japan or China. Only five cases from the United States have previously been reported, of which three patients were of European ancestry. Here, we present the fourth case of lipoprotein glomerulopathy in a European-American man. Whereas prior European-American patients with lipoprotein glomerulopathy were found to have the previously reported apoE Kyoto genotype, the patient presented here was found to have a novel mutation that we have named apoE Las Vegas.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20624773     DOI: 10.1093/ndt/gfq389

Source DB:  PubMed          Journal:  Nephrol Dial Transplant        ISSN: 0931-0509            Impact factor:   5.992


  10 in total

1.  Lipoprotein Glomerulopathy, First Case Report from Canada.

Authors:  Julie Anne Ting; Susanna A McRae; Daniel Schwartz; Sean J Barbour; Maziar Riazy
Journal:  Int J Nephrol Renovasc Dis       Date:  2022-06-21

Review 2.  An Updated Review and Meta Analysis of Lipoprotein Glomerulopathy.

Authors:  Meng-Shi Li; Yang Li; Yang Liu; Xu-Jie Zhou; Hong Zhang
Journal:  Front Med (Lausanne)       Date:  2022-05-06

Review 3.  Apolipoprotein E mutations: a comparison between lipoprotein glomerulopathy and type III hyperlipoproteinemia.

Authors:  Akira Matsunaga; Takao Saito
Journal:  Clin Exp Nephrol       Date:  2014-02-26       Impact factor: 2.801

Review 4.  A possible structural basis behind the pathogenic role of apolipoprotein E hereditary mutations associated with lipoprotein glomerulopathy.

Authors:  Efstratios Stratikos; Angeliki Chroni
Journal:  Clin Exp Nephrol       Date:  2013-10-23       Impact factor: 2.801

5.  Thermodynamic destabilization and aggregation propensity as the mechanism behind the association of apoE3 mutants and lipoprotein glomerulopathy.

Authors:  Maria Katsarou; Efstratios Stratikos; Angeliki Chroni
Journal:  J Lipid Res       Date:  2018-10-11       Impact factor: 5.922

6.  Lipoprotein Glomerulopathy in a Hispanic Female: A Case Report and Literature Review.

Authors:  Nasma K Majeed; Jeanette McLaughlin; Miguel Gonzalez
Journal:  Can J Kidney Health Dis       Date:  2019-06-27

7.  A novel apolipoprotein E mutation, ApoE Ganzhou (Arg43Cys), in a Chinese son and his father with lipoprotein glomerulopathy: two case reports.

Authors:  Runxiu Wang; Chengbo Zhao; Wen Chen; Zhiping Liu; Fuhua Xie
Journal:  J Med Case Rep       Date:  2022-02-23

8.  Whole Exome Sequencing Reveals a Novel APOE Mutation in a Patient With Sporadic Early-Onset Alzheimer's Disease.

Authors:  Jaya Bagaria; Yeonsil Moon; Eva Bagyinszky; Kyu Hwan Shim; Seong Soo A An; SangYun Kim; Seol Heui Han
Journal:  Front Neurol       Date:  2022-06-10       Impact factor: 4.086

9.  Lipoprotein glomerulopathy resulting from compound heterogeneous mutations of APOE gene: A case report.

Authors:  Yunsi Li; Jin Chen; Yurong Zou; Wei Wang; Guisen Li
Journal:  Medicine (Baltimore)       Date:  2022-02-04       Impact factor: 1.889

10.  Lipoprotein glomerulopathy associated with the Osaka/Kurashiki APOE variant: two cases identified in Latin America.

Authors:  Joaquim Nelito da Silveira-Neto; Guilherme Jinson de Oliveira Ahn; Precil Diego Miranda de Menezes Neves; Vinicius Augusto Ferreira Baptista; Stanley de Almeida Araújo; David Campos Wanderley; Andréia Watanabe; Elieser Hitoshi Watanabe; Neide Missae Murai; Eny Maria Goloni Bertollo; Osvaldo Merege Vieira-Neto; Márcio Dantas; Sergio Ricardo de Antônio; Roberto Silva Costa; Maria Alice Sperto Ferreira Baptista; Miguel Moysés-Neto; Luiz Fernando Onuchic
Journal:  Diagn Pathol       Date:  2021-07-26       Impact factor: 2.644

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.